The Prosthetic Joint Infection (PJI) market encompasses a comprehensive suite of diagnostic and therapeutic solutions designed to detect, prevent, and manage infections following hip and knee arthroplasty procedures. Key products include rapid microbiological assays, advanced imaging platforms, antibiotic-loaded bone cement and implant coatings, as well as adjunctive antimicrobial therapies.

Prosthetic Joint Infection Market offerings deliver critical advantages such as early pathogen identification, reduced revision surgery rates, and enhanced patient recovery, directly addressing major market challenges in postoperative care. With the global rise in osteoarthritis and other degenerative joint disorders among aging populations, there is a growing need for reliable PJI management tools that curb healthcare costs and improve outcomes. Additionally, increasing focus on personalized medicine and adoption of novel biocompatible materials is stimulating market growth. The market scope extends across hospitals, diagnostic laboratories, and orthopedic clinics, where clinicians rely on integrated solutions to counteract postoperative complications. Recent market forecast reports highlight positive industry trends and underscore the need for continued innovation in PJI management.

The prosthetic joint infection market is estimated to be valued at USD 67.7 Mn in 2025 and is expected to reach USD 97.8 Mn by 2032, growing at a compound annual growth rate (CAGR) of 5.4% from 2025 to 2032.

Get More insights on: Prosthetic Joint Infection Market

Get this Report in Japanese Language: 人工関節感染症市場

Get this Report in Korean Language: 인공관절감염시장